Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 387-394

  Yasar, Sevil ^a   Justinova, Zuzana ^b,c   Lee, Sun Hee ^b,d   Stefanski, Roman ^b,e   Goldberg, Steven R ^b   Tanda, Gianluigi ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Korea Food and Drug Administration   (South Korea)

^e INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; COCAINE; METHAMPHETAMINE; MONOAMINE OXIDASE B INHIBITOR; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE; PROADIFEN; SELEGILINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABUSE; DRUG DISCRIMINATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOTRANSFORMATION; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; MONOAMINE OXIDASE INHIBITORS; PHENETHYLAMINES; RATS; RATS, INBRED F344; SELEGILINE;

EID: 33645131794     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.096263     Document Type: Article

References (47)

1. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, and Amini H (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27:841-845.
2. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208-214.
3. Barroso N and Rodriguez M (1996) Action of beta-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission. Eur J Pharmacol 297:195-203.
4. Bergman J, Yasar S, and Winger G (2001) Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology (Berl) 159:21-30.
5. Berry MD, Scarr E, Zhu MY, Paterson IA, and Juorio AV (1994) The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine. Br J Pharmacol 113:1159-1166.
6. Bondareva TS, Young, and Glennon RA (2002) Central stimulants as discriminative stimuli: asymmetric generalization between (-)ephedrine and S(+)methamphetamine. Pharmacol Biochem Behav 74:157-162.
7. Carlsson A, Davis JN, Kehr W, Lindqvist M, and Atack CW (1972) Stimultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch Pharmacol 275:153-168.
8. Cesura AM, Imhof R, Galva MD, Kettler R, and Da Prada M (1988) Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. Pharmacol Res Commun 20 (Suppl 4):51-61.
9. Colpaert FC, Niemegeers CJE, and Janssen PA (1979) Discriminative stimulus properties of cocaine: neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol Biochem Behav 10:535-546.
10. Da Prada M, Kettler R, Keller HH, Bonetti EP, and Imhof R (1987) Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol 45:175-178.
11. D'Mello GD and Stolerman IP (1977) Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats. Br J Pharmacol 61:415-422.
12. Dyck LE (1984) The behavioural effects of phenelzine and phenylethylamine may be due to amine release. Brain Res Bull 12:23-28.
13. Ebadi M, Sharma S, Shavali S, and El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67:285-289.
14. Engberg G, Elebring T, and Nissbrandt H (1991) Deprenyl (Selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 259:841-847.
15. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, and O'Malley SS (2003) A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 53:136-143.
16. Gelowitz DL, Richardson JS, Wishart TB, Yu PH, and Lai CT (1994) Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 47:41-45.
17. Glennon RA, Young R, Hauck AE, and Mckenney JD (1984) Structure-activity studies on amplhetamine analogs using drug discrimination methodology. Pharmacol Biochem Behav 21:895-901.
18. Grasing K and Ghosh S (1998) Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal. Neuropharmacology 37:1007-1017.
19. Haberle D, Szoko E, and Magyar K (2002) The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 9:47-51.
20. Heinonen EH, Anttila MI, and Lammintausta RA (1994) Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749.
21. Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, and Bigelow GE (2004) Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl) 172:31-40.
22. Lajtha A, Sershen H, Cooper T, Hashim A, and Gaal J (1996) Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Neurochem Res 21:1155-1160.
23. Lamensdorf I and Finberg JP (1997) Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl. Neuropharmacology 36:1455-1461.
24. Magyar K and Haberle D (1999) Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology 7:175-190.
25. Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, and Szoko E (2004) Pharmacological aspects of (-)-deprenyl. Curr Med Chem 11:2017-2031.
26. Magyar K and Szende B (2004) (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25:233-242.
27. Melega WP, Cho AK, Schmitz D, Kuczenski R, and Segal D (1999) l-Methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J Pharmacol Exp Ther 288:752-758.
28. Okuda C, Segal DS, and Kuczenski R (1992) Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacol Biochem Behav 43:1075-1080.
29. Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, and Boulton AA (1995) Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain. Neurochem Res 20:1503-1510.
30. Paterson IA, Juorio AV, Berry MD, and Zhu MY (1991) Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther 258:1019-1026.
31. Sannerud CA, Kaminski BJ, and Griffiths RR (1996) Intravenous self-injection of four novel phenethylamines in baboons. Behav Pharmacol 7:315-323.
32. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
33. Shannon HE and Degregorio CM (1982) Self-administration of the endogenous trace amines beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs. J Pharmacol Exp Ther 222:52-60.
34. Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, and Gainetdinov RR (2004) Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem 91:362-373.
35. Tariot PN, Goldstein B, Podgorski CA, Cox C, and Frambes N (1998) Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. Am J Geriatr Psychiatry 6:145-154.
36. Timar J and Knoll B (1986) The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats. Arch Int Pharmacodyn Ther 279:50-60.
37. Treseder SA, Rose S, Summo L, and Jenner P (2003) Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm 110:229-238.
38. Winger GD, Yasar S, Negus SS, and Goldberg SR (1994) Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther 56:774-780.
39. Wu WR and Zhu XZ (1999) The amphetamine-like reinforcing effect and mechanism of L-deprenyl on conditioned place preference in mice. Eur J Pharmacol 364:1-6.
40. Yasar S and Bergman J (1994) Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 56:768-773.
41. Yasar S, Gaal J, Justinova Z, and Bergman J (2005a) Discriminative stimulus and reinforcing effects of p-fluoro-L-deprenyl in monkeys. Psychopharmacology (Berl) 182:95-103
42. Yasar S, Gaal J, Panlilio LV, Justinova Z, Redhi G, and Schindler CW (2005b) A comparison of drug-seeking behavior maintained by D-amphetamine, l-deprenyl (selegiline) and d-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology (Berl) 183:413-421
43. Yasar S, Goldberg JP, and Goldberg SR (1996) Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm 48 (Suppl):61-73.
44. Yasar S, Schindler CW, Thorndike EB, and Goldberg SR (1994) Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats. Eur J Pharmacol 259:243-250.
45. Yasar S, Schindler CW, Thorndike EB, Szelenyi I, and Goldberg SR (1993) Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J Pharmacol Exp Ther 265:1-6.
46. Yokel RA and Pickens R (1973) Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther 187:27-33.
47. Yoshida T, Oguro T, and Kuroiwa Y (1987) Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. Xenobiotica 17:957-963.